Success Metrics

Clinical Success Rate
33.3%

Based on 1 completed trials

Completion Rate
33%(1/3)
Active Trials
1(25%)
Results Posted
200%(2 trials)
Terminated
2(50%)

Phase Distribution

Ph phase_2
1
25%
Ph phase_1
1
25%
Ph phase_4
2
50%

Phase Distribution

1

Early Stage

1

Mid Stage

2

Late Stage

Phase Distribution4 total trials
Phase 1Safety & dosage
1(25.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 4Post-market surveillance
2(50.0%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

33.3%

1 of 3 finished

Non-Completion Rate

66.7%

2 ended early

Currently Active

1

trials recruiting

Total Trials

4

all time

Status Distribution
Active(1)
Completed(1)
Terminated(2)

Detailed Status

Terminated2
Completed1
Recruiting1

Development Timeline

Analytics

Development Status

Total Trials
4
Active
1
Success Rate
33.3%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (25.0%)
Phase 21 (25.0%)
Phase 42 (50.0%)

Trials by Status

completed125%
recruiting125%
terminated250%

Recent Activity

1 active trials
Showing 4 of 4
completedphase_1

Treatment of Familiar Lymphohistiocytosis

NCT02472054
recruitingphase_2

Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A

NCT06802055
terminatedphase_4

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

NCT00332839
terminatedphase_4

Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program

NCT00956293

Clinical Trials (4)

Showing 4 of 4 trials
NCT02472054Phase 1

Treatment of Familiar Lymphohistiocytosis

Completed
NCT06802055Phase 2

Efficacy and Safety of Sirolimus With or Without Cyclosporin A in Chinese Patients With Aplastic Anemia Refractory/Intolerant to Cyclosporin A

Recruiting
NCT00332839Phase 4

Comparison of CNI-based Regimen Versus CNI-free Regimen in Kidney Transplant Recipients.

Terminated
NCT00956293Phase 4

Study to Evaluate the Efficacy, Safety and Tolerability of Everolimus in de Novo Renal Transplant Recipients Participating in the Eurotransplant Senior Program

Terminated

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4